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Use of enoxaparin in patients with 
heparin-induced thrombocytopenia syndrome 
Milton M. Slocum, MD, John G. Adams, Jr., MD, Rosemary Teel, MT, 
Donald P. Spadone, MD, and Donald Silver, MD, Columbia, Mo. 
Pro'pose: To determine whether low molecular weight heparin (LMWH) can be an 
alternative to unfractionated heparin (UH) for patients with heparin-induced throm- 
bocytopenia syndrome (HIT). 
Methods: The diagnosis of HIT was established in 126 patients by platelet aggregometry 
with UH (1 U/ml). These plasma samples were also tested for the ability to aggregate 
platelets in the presence of the LMWH enoxaparin (1 U/ml). Two patients with the HIT 
syndrome, after negative platelet aggregometry testing with enoxaparin, were antieoagu- 
lated with enoxaparin. 
Results: Fifteen plasma samples that tested negative to UH also tested negative to 
enoxaparin. Forty-three of 126 (34%) UH-positive plasma samples aggregated platelets in 
the presence of enoxaparin. Twenty-two f 102 (22%) plasma samples with limited positive 
aggregation responses (minimal or no change in optical density) aggregated platelets in the 
presence of enoxaparin. However, 21 of 24 (88%) strongly positive plasma samples (30% 
to 60% change in optical density at 3 to 27 minutes) also aggregated platelets in the 
presence ofenoxaparin. Two patients with HIT who received enoxaparin after aggregation 
testing demonstrated nocross-reactivity to enoxaparin achieved adequate anticoagulation 
and did not develop HIT. 
Conclusions: Thirty-four percent of plasma samples from patients with HIT (88% of those 
strongly positive) aggregated platelets in the presence of enoxaparin. Patients with HIT 
may safely receive noxaparin if their plasma does not aggregate platelets in the presence 
of enoxaparin. (J Vasc Surg 1996;23:839-43.) 
Heparin-induced thrombocytopenia (HIT) is a 
dose-independent reaction to heparin that is caused 
by heparin- associated antiplatelet antibodies (HAAb) 
and occurs in 2% to 4% of patients receiving heparin. 
The thrombocytopenia usually occurs 5 to 14 days 
after initiation of heparin therapy but may occur 
immediately upon re-exposure to heparin. H IT  is 
associated with thromboembolic complications in 
22% to 61% of patients ~'2 and with hemorrhagic 
complications in 5% of patients. 3 
Because heparin is used so frequently, a large 
number of patients will develop heparin-associated 
antiplatelet antibodies. It is accepted that antico- 
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agulation with heparin should be avoided in pa- 
tients with HIT; however, these patients commonly 
have illnesses that require continued anticoagulation 
with an agent that may be rapidly titrated to effect. 
This need has prompted the search for alternatives 
to unfractionated heparin (UH) in patients with 
HIT. 
When low molecular weight heparins (LMWHs) 
and heparinoids were introduced, it was believed that 
they would have application as a substitute for UH in 
patients with HIT; however, clinical studies have 
produced conflicting results. Some investigators e- 
port resolution of thrombocytopenia, 412 whereas 
others report persistent thrombocytopenia. ~3 16 Pre- 
viously published ata from our laboratory revealed 
that thc LMWHs mono-embolex NM and fragmin 
and the heparinoid Org 10172 have the ability to 
aggregate platelets (60.8%, 25.5%, and 19.6%, respec- 
tively) in the presence of HAAb) 7 This study evalu- 
ated the ability ofcnoxaparin to aggregate platelets in 
the presence of HAAb and the value ofenoxaparin 
managing patients with HIT. 
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METHODS 
From November 1993 through March 1995, all 
plasma samples from patients suspected of having 
HIT that aggregated platelets in the presence of beef 
or pork heparin were also tested with enoxaparin. The 
first 15 plasma samples that did not aggregate platelets 
in the presence of UH were also tested with enox- 
aparin. HIT was suspected in patients receiving any 
form of UH when at least one of the following was 
present: platelet count <100,000 mm 3 or substantial 
decrease (>15%) in the platelet count during heparin 
administration, resistance to anticoagulation with 
heparin, or thrombohemorrhagic event(s) while re- 
ceiving heparin. 
This study was approved by the Institutional 
Review Board of the University of Missouri Hospital 
and Clinics. 
Our method for platelet aggregometry has been 
reported in detail. ~8 Platelet rich plasma (PRP, 0.16 
ml) from an unaffected onor was combined with 
platelet-poor plasma (PPP, 0.24 ml) from the patient. 
UH (1 U/ml) was added to this plasma. Platelet 
aggregation was detected with a platelet aggregom- 
eter (Chronolog Corp., Haverton, Penn.) and con- 
firmed by visual inspection. 
Adenosine diphosphate, a potent stimulator of 
platelet aggregation, was used to confirm the ability of 
the donor platelets to aggregate. Incubations of PRP 
and saline, PRP and heparin, and PPP and saline were 
performed to rule out nonspecific aggregation. False- 
positive results were ruled out by placing the patient's 
PPP, normal PRP, and a higher concentration of 
heparin (100 U/ml) in the aggregometer. Aggrega- 
tion occurring in the presence of a higher heparin 
concentration i dicated a false-positive r sult.I9 
A positive result was assigned only when appro- 
priate responses were present in all controls and 
platelet aggregation was seen when test PPP, normal 
PRP, and low-dose heparin were combined. The 
positive aggregation responses were subclassified into 
weak-positive and strong-positive on the basis of the 
following criteria: a weak aggregation response was 
assigned to those specimens with distinct aggregation 
visually noted after 27 minutes of incubation and 
minimal or no change in optical density; strong 
aggregation responses were characterized by aggre- 
gation before 27 minutes of incubation and a 30% to 
60% increase in optical density. All plasmas with a 
positive aggregation response to UH were also tested 
with enoxaparin i  the aggregometer. 
Two patients with the HIT syndrome who tested 
negative for enoxaparin and who required further 
anticoagulation received enoxaparin. 
RESULTS 
Between November 1993 and March 1995, 126 
patients (94 men, 32 women) with HAAb were 
identified with platelet aggregometry. Twenty-threc 
plasma samples were referred to our lab for testing, 
and 103 were from patients in our health science 
center. Of the 126 plasma samples testing positive for 
HAAb, 43 (34%) also aggregated platelets in the 
presence of cnoxaparin. 102 of 126 samples were 
graded as weak positives; only 22 (22%) of these 
aggregated platelets in the presence of enoxaparin. 
The remaining 24 samples had a strong platelet 
aggregation response to UH; 21 (88%) of these 
aggregated platelets in the presence of enoxaparin. 
The 15 plasma samples that tested negative to UH 
also tested negative to enoxaparin (Fig. 1). 
During the study period, two patients with the 
HIT syndrome clinically required further anticoagu- 
lation. Each had a weak-positive aggregation response 
in the presence of UH, and neither aggregated 
platelets in the presence of enoxaparin. 
The first patient was a 69-year-old white man who 
underwent emergent repair of a ruptured abdominal 
aortic aneurysm. His postoperative course was com- 
plicated by acute renal failure requiring hemodialysis. 
On admission, his platelet count was 165,000 mm 3. 
While rcceiving heparin for hemodialysis, his platelet 
count fell to 46,000 mm ~. On postoperative day 10, 
HAAb were documented by platelet aggregometry b
UH. Enoxaparin did not induce platelet aggregation 
when combined with donor platelets and the patient's 
plasma; it was therefore used as an anticoagulant for 
hemodialysis. Platelet counts increased after institu- 
tion ofenoxaparin therapy to a high of 303,000 mm 3 
(range 136,000 mm 3 to 303,000 ram3). He received 
enoxaparin three times per week during hemodialysis 
until he died from adult respiratory distress yndrome 
and multisystem organ failure on postoperative day 
54. No further thrombocytopenia or thrombohem- 
morhagic omplications were noted. 
The second patient was an 80-year-old white man 
who had severe abdominal pain, hypotension, and 
abdominal distention. His platelet count at the time 
of admission was 192,000 mm 3. Emergent lapa- 
rotomy revealed a large retroperitoneal hematoma 
with active bleeding posterior to the body of the 
pancreas. No visceral aneurysms or other bleeding 
sites were encountered. An intracardiac thrombus was 
postoperatively documented by echocardiography 
and treated with UH. Several days after institution of 
UH therapy, his platelet count had fallen to 82,000 
mm 3 and HAAb were documented by platelet aggre- 
gometry. Enoxaparin did not induce platelet 
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Fig. 1. Enoxaparin cross-reactivity n patients with heparin-induced thrombocytopenia 
syndrome. 
aggregation; therefore, during the 2 weeks it was used 
for management of the mural thrombus, no further 
thrombocytopenia or thromboembolic sequelae were 
noted. 
DISCUSSION 
HIT, described in 1973, 2° has been recognized as 
a specific immune-mediated syndrome inwhich anti- 
platelet antibodies are generated in the presence of 
heparin. HIT occurs in 2% to 4% of patients exposed 
to any amount ofheparin delivered by any route. The 
syndrome may occur in the presence of very small 
amounts ofheparin (o e unit per hour); even heparin- 
coated venous catheters have been implicated as 
causative agents in this syndrome.3 Patients of any age 
are at risk for developing HAAb; the syndrome has 
been documented in infants. 21HAAb may develop 
regardless of the type of heparin. It has been known 
that beef and pork heparin induce HAAb; it has 
recently been shown that enoxaparin may induce 
Haa b ,22 
HAAb develop 5to 14 days after the first exposure 
to heparin. However, one must be aware that throm- 
bocytopenia and thrombosis may occur immediately 
upon response to heparin in a patient who developed 
HAAb during a previous exposure to heparin. Be- 
cause of this, the platelet count should be determined 
before heparin administration and daily thereafter. 
HIT should be suspected in a patient receiving any 
form of heparin when any one of the following 
develop: thrombocytopenia (pl telet count < 100,000 
mm 3 or a substantial decrease in the count), resistance 
to anticoagulation with heparin, or thrombohemor- 
rhagic complications while receiving heparin. When 
HIT is suspected, all forms of heparin should be 
discontinued and the patient's plasma tested for the 
presence of HAAb. If HIT is confirmed, the platelet 
count should begin to rise and thromboembolic 
events hould cease upon discontinuation fheparin. 
Discontinuation of heparin therapy is the key to 
improving morbidity and mortality; morbidity and 
mortality are as high as 61% and 23% when heparin is 
continued, but may be reduced to 22% and 12%, 
respectively, when the syndrome is recognized and 
heparin discontinued. 3 The mortality approaches 90% 
in patients with hemorrhagic (rather than throm- 
boembolic) manifestations of HIT; fortunately, only 
5% of patients with HIT have hemorrhagic complica- 
tions. With heightened awareness of the syndrome 
and the prompt discontinuation fheparin, the mor- 
bidity and mortality may be reduced to rates ap- 
proaching 0.17 
Heparin-induced antibodies (usually IgG) are 
responsible for the platelet activation and aggregation 
noted in HIT syndrome. The antibodies appear to be 
specific for heparin because heparin may be used to 
remove the antibodies from plasma and because 
heparin excess can prevent platelet aggregation i
HAAb plasmas. 19 Furthermore, patients with HIT 
have antibodies that react with heparin in a classic 
F( abl)2 reacti°n-23 
Drugs that inhibit platelet function or oral anti- 
coagulants such as warfarin are appropriate substi- 
tutes for many patients with HIT. However, many of 
these patients continue to require therapy with an 
anticoagulant that allows rapid titrating of effects. 
Because LMWHs and heparinoids are as effective as 
UH in preventing thrombus formation, they have 
been used prophylactically forthe prevention of deep 
venous thrombosis. 24'2a LMWH has a lower anti- 
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thrombin activity than UH and, therefore, a de- 
creased incidence of  bleeding complications. 2s,26 Im- 
portantly, LMWH interacts differently with platelets 
than UH.  Idiosyncratic platelet aggregation occurs 
less frequently with LMWH than with UH;  26 in 
high concentrations (equivalent to 100 U /ml  UH) ,  
LMWH does not inhibit platelet aggregation with 
ristocetin as does UH;  and LMWH inhibits collagen- 
induced platelet aggregation to a lesser degree than 
UH.  27 
Initially it was thought  that these differences 
would lead to a lower incidence of  HIT.  LMWH was 
therefore used in several clinical trials in patients with 
HIT.  These trials produced conflicting results; some 
investigators found that patients with H IT  had re- 
versal o f  their thrombocytopenia while receiving 
LMWH,  412 whereas others found that the throm- 
bocytopenia persisted.1316 We have previously docu- 
mented that the LMWHs mono-embolex NM and 
fragmin and the heparinoid Org 10172 have the 
ability to aggregate platelets in the presence of  
HAAb. 17 On the basis o f  these previous studies and 
on this study, which showed a high incidence of  
platelet aggregation in the presence of  enoxaparin, 
we recommend that plasma from all patients with 
H IT  who are being considered for treatment with 
LMWH undergo testing to ensure that the LMWH 
will not  aggregate platelets in the presence of  the 
patient's plasma. 
As described, we have identified 83 patients with 
documented H IT  whose plasma did not aggregate 
platelets in the presence of  enoxaparin. Two of  these 
patients required further heparin-like anticoagulation 
and safely received enoxaparin. 
Thus although enoxaparin induces platelet aggre- 
gation in up to 34% of  plasmas from patients with 
HIT ,  it may be safely used as a substitute for UH in 
those patients whose plasma does not aggregate 
platelets in the presence of  enoxaparin. 
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D ISCUSSION 
Dr. Thomas W. Wakefield (Ann Arbor, Mich.). The 
Missouri group is again on the forefront concerning the 
heparin-induced thrombocytopenia, or HIT, syndrome. In 
this study, 34% of positive plasma (as assessed by platelet 
aggregometry) in the presence of unfractionated heparin 
were positive for the low molecular weight heparin enox- 
aparin. Subdividing plasmas into positive categories, 88% 
of strongly positive plasmas with unfractionated heparin 
aggregated platelets in the presence of enoxapatin, whereas 
only 22% of limited positive plasmas with unfractionated 
heparin aggregated platelets in the presence ofenoxaparin. 
Two patients with HIT syndrome who tested negative 
for enoxaparin safely received this low molecular weight 
heparin. 
The in vitro method of testing for aggregation activity 
against he heparin in question is an excellent approach in 
the situation of HIT. I totally agree with the authors' 
conclusion that if the aggregation test against low molecular 
weight heparin is negative, one can safely use that hepatin 
for anticoagulation. I have three short questions: 
Have you had any experience using 14C-serotonin 
testing for HIT? Many laboratories use this test for diag- 
nosing HIT in preference to aggregometry, and I wonder if 
the use of 14C-serotonin testing would improve accuracy 
even further? 
Have you used low molecular weight heparins other 
than enoxaparin, and what is your experience with the 
heparinoid Org 10172? The incidence of HIT may be even 
lower with a low molecular weight heparin of very small size 
and an even greater antifactor Xa/antifactor IIa ratio than 
enoxaparin. 
Finally, in day-to-day practice, when faced with the 
syndrome of HIT, which one of the heparin substitutes 
would be your first choice to use? 
Dr. Mi lton Slocum. Your first question about ~4C- 
serotonin release testing for HIT: in our continuing effort 
to improve the accuracy of identifying plasmas that contain 
heparin-associated antiplatelet antibodies, we have evalu- 
ated many of the existing methods for determining the 
presence of heparin-associated antiplatelet antibodies and 
have found that the correlation between tiC-serotonin 
release and platelet aggregometry is very good. In addition, 
we are developing an ELISA assay that may identify heparin- 
associated antiplatelet antibodies more accurately and more 
quicldy. 
Your next question concerns Organon 10172. Several 
years ago our laboratory published a paper in which the 
heparinoid and several low molecular weight heparins were 
studied the same way we studied enoxaparin i  this paper. 
We found that the cross-reactivity to Org 10172 was less 
than that ofenoxaparin (i9.6%). We have not used Organon 
10172 clinically. 
Your last question is, "In day-to-day practice, what 
agent do we chose?" Our current practice is that every 
plasma that tests positive to unfractionated heparin, 
whether it be beef or pork, also automatically undergoes 
testing with enoxaparin. If the patient is judged to require 
a heparin-like agent for anticoagulation, we will use enox- 
aparin if the patient has tested negative to it. Otherwise, we 
block platelet function with aspirin and use limited amounts 
of heparin. 
Dr. John D. Corson (Iowa City, Iowa). I was a little 
concerned about his epidemic of HIT in Missouri because 
we are not very far from you. Over what period of time 
where these 126 patients identified or were these samples 
sent to you by outside people? 
Dr. Slocum. It is over about a 2 to 21/2 year period, and 
a number of our samples are referred to us from other 
institutions. 
